Photo: Paolo Tarantino/Twitter
Jun 10, 2023, 02:53
Patients progressing on 1L palbo should not receive further exposure to palbo- Paolo Tarantino
Consistent with the PACE trial, the PALMIRA randomized phase 2 trial showed no benefit in terms of PFS or OS with the use of palbociclib beyond progression to 1L ET+palbo. Patients progressing on 1L palbo should not receive further exposure to palbo. #ASCO23
Source: Paolo Tarantino/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 23, 2025, 21:19
Jan 23, 2025, 21:18
Jan 23, 2025, 21:18
Jan 23, 2025, 21:18
Jan 23, 2025, 21:18
Jan 23, 2025, 21:18
Jan 23, 2025, 21:18
Jan 23, 2025, 20:48